Table 3.
Induction therapy after diagnosis according to the disease groups.
| L1 | L2 | L3 | UC | IBD-U | |
|---|---|---|---|---|---|
| (N = 182) | (N = 52) | (N = 782) | (N = 653) | (N = 111) | |
| Receive induction therapy | 166 (91.2%) | 49 (94.2%) | 741 (94.8%) | 620 (94.9%) | 102 (91.9%) |
| Antibiotics | 15 (9.0%) | 7 (14.3%) | 90 (12.1%) | 43 (6.9%) | 14 (13.7%) |
| Mesalazine/sulfasalazine | 73 (44.0%) | 6 (12.2%)*a,b,c,d | 410 (55.3%) | 471 (76.0%) | 77 (75.5%) |
| Exclusive enteral nutrition therapy (EEN) | 57 (34.3%) | 5 (10.2%)*a,b | 247 (33.3%) | 15 (2.4%) | 10 (9.8%) |
| Corticosteroids | |||||
| Systemic | 61 (36.7%) | 20 (40.8%) | 271 (36.6%) | 251 (40.5%) | 28 (27.5%) |
| Rectal | 1 (0.6%) | 3 (6.1%) | 16 (2.2%) | 18 (2.9%) | 3 (2.9%) |
| Immunomodulators | 18 (10.8%) | 11 (22.4%) | 242 (32.7%) | 135 (21.8%) | 11 (10.8%) |
| Tacrolimus | 0 | 0 | 0 | 0 | 0 |
| Methotrexate | 0 | 1 (9.1%) | 6 (2.5%) | 2 (1.5%) | 1 (9.1%) |
| Azathioprine | 16 (88.9%) | 9 (81.8%) | 235 (97.1%) | 123 (91.1%) | 10 (90.9%) |
| Cyclosporin A | 2 (11.1%) | 1 (9.1%) | 1 (0.4%) | 10 (7.4%) | 0 |
| Biologicals | 3 (1.8%) | 1 (2.0%) | 36 (4.9%) | 7 (1.1%) | 2 (2.0%) |
| Adalimumab | 0 | 0 | 1 (2.8%) | 0 | 0 |
| Infliximab | 3 (100%) | 1 (100%) | 29 (80.5%) | 5 (71.4%) | 2 (100%) |
| Other | 0 | 0 | 6 (16.7%) | 2 (28.6%) | 0 |
*
p < 0.05 Student's t-test.
a
L2 vs. L1.
b
L2 vs. L3.
c
L2 vs. UC.
d
L2 vs. IBD-U.